Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines
- First Online:
- 112 Downloads
Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade®) in combination with cetuximab in squamous cell carcinoma cell lines (SCC).
Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay.
Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P < 0.042), and the activity was further significantly enhanced by the addition of cetuximab (P < 0.043).
Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.
KeywordsBortezomib Cetuximab Squamous cell carcinoma cell lines Growth inhibition Cytotoxicity
- Ling YH, Liebes L, Zou Y, Perez-Soler R (2003b) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278:33714–33723. doi:10.1074/jbc.M302559200 PubMedCrossRefGoogle Scholar
- Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955PubMedGoogle Scholar
- Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171–2177. doi:10.1200/JCO.2006.06.7447 PubMedCrossRefGoogle Scholar
- Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H et al (2008a) Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134:323–330. doi:10.1007/s00432-007-0287-9 PubMedCrossRefGoogle Scholar